Codexis Inc (4QK F) stock market data APIs
€2.0329
0.08(3.9%)
as of June 27, 2025
Try our APIs with
free plan!
Codexis Inc Financial Data Overview
Price chart is built with
Anychart
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Prev. Close
2.0329
Open
2.1138
High
2.1138
Low
1.9865
52 wk Range
1.723-5.645
Market Cap
169 M
Shares Outstanding
82 845 K
Revenue
49 815 K
EPS
-0.07
Beta
2.532
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Codexis Inc data using free add-ons & libraries
Get Codexis Inc Fundamental Data
Codexis Inc Fundamental data includes:
- Net Revenue: 49 815 K
- EBITDA: -62 063 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Codexis Inc News
New
The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
It is a pleasure to report that the Codexis, Inc. (NASDAQ:CDXS) is up 46% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churning. I...
Baillie Gifford Trims Position in Codexis Inc
Overview of Baillie Gifford (Trades, Portfolio)'s Recent Transaction Warning! GuruFocus has detected 6 Warning Signs with CDXS. On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned i...
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Codexis, Inc. Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs REDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -...
Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company
Codexis, Inc. (NASDAQ:CDXS) shares have continued their recent momentum with a 41% gain in the last month alone. Unfortunately, the gains of the last month did little to right the losses of the last y...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
